Illinois Clinical Trials for Pleural Mesothelioma
1. University of Chicago (Chicago, IL)
Name of Study:
A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
Study type:
Interventional
Purpose:
To give S-588210 –peptide vaccine in mpm patients without progression of disease after receiving chemotherapy
ClinicalTrials.gov Identifier:
NCT02661659
Status:
Currently recruiting February 2016- February 2018 Estimated enrollment 16 participants
Location:
University of Chicago
Contact:
Rose Buerkley
773-834-4002
brose@bsd.uchicago.edu
Mewish Ahmad
773-834-1472
mahmad3@medicine.bsd.uchicago.edu
2. University of Chicago (Chicago, IL)
Name of Study:
A Pilot Window of Opportunity Study of the Anti-PD-1 Antibody Pembrlizumab in Patients With Resectable Malignant Pleural Mesothelioma
Study type:
Interventional
Purpose:
Patients will undergo a pretreatment PET/CT scan for clinical staging and a VATS procedure to acquire pretreatment tissue. Three cycles of Pembrolizmab will be given and another PET/CT scan to assess response. Surgical resection will take place 4 weeks after third dose of chemotherapy given. Standard chemotherapy will be given 6-8 weeks after surgery after another CT scan. Ct scans will be done every 2 cycles of chemotherapy in evaluate response. After chemotherapy is finished optional pembrolzumab will be given to eligible patients for 1-year post surgery.
ClinicalTrials.gov Identifier:
NCT02707666
Status:
Currently recruiting February 2016 – March 2018 – Estimated enrollment 15 participants
Location:
University of Chicago
Contact:
Rose Buerkley
773-834-4002
brose@bsd.uchicago.edu
Mewish Ahmad
773-834-1472
mahmad3@medicine.bsd.uchicago.edu
3. University of Chicago (Chicago, IL)
Name of Study:
Pembrolizumab in Treating Patients With Malignant Mesothelioma
Study type:
Interventional
Purpose:
This Phase ll trial studies how well pembrolizumab works in treating patients with malignant mesothelioma, a cancer of the linings around the lungs (pleura) or abdomen (peritoneum). Monoclonal antibodies, such as pembrolizumab, work by blocking a protein called programmed cell death l (PD-l) which may stimulate an immune response and kill tumor cells
ClinicalTrials.gov Identifier:
NCT02399371
Status:
Enrolling- Start date March 2015 Completion date March 2018; Estimated enrollment 65
Location:
University of Chicago, Chicago Illinois 60637
Contact:
Hedy L. Kindler
773-702-0360
hkindler@medicine.bsd.uchicago.edu
Mesothelioma Clinical Trial Information
Learn More About Mesothelioma
Did You Know?
Get Help from Experienced Mesothelioma Nurses
Learn more about these experienced mesothelioma nurses by watching the video below. Click here to contact a mesothelioma nurse now.
Learn More About MesoLawyersCare
Watch the video below to learn why MesoLawyersCare is the best choice to represent you and your family after a mesothelioma diagnosis.
Contact MesoLawyersCare Now
If you or a loved one has been diagnosed with mesothelioma, please contact us to see if we can help you get the compensation you deserve from the billions of dollars in asbestos trust funds available now for qualified asbestos victims. With just one call, you can put all our experience and success to work for you.
We have represented thousands of victims of mesothelioma and their families in virtually every State in the country and in decades of work have recovered billions of dollars in financial compensation for our clients.
Call us now at 1-888-568-1177, fill out the form on this page or chat with a live person. The consultation is free and it costs nothing upfront to hire the lawyers behind MesoLawyersCare. We only get paid if you collect a settlement or verdict and you will never receive a bill from us.
Receive a
FREE No Obligation
Legal Consultation Today
Important Notice: We are unable to help if:
- Diagnosis or passing was more than three years ago
- An attorney has already been retained in this matter
“You have all been so wonderful to us, so professional, and always looking out for our best interests in every way. I know it’s a job you do. However, not once did anyone ever make us feel like we did not matter.”